Ozempic on the NHS: Who Qualifies & What It Costs in the UK (2026)

Overview

Ozempic is the brand name for semaglutide at doses of 0.5 mg and 1 mg (and now 2 mg), developed by Novo Nordisk primarily as a treatment for type 2 diabetes. In the UK, Ozempic is licensed by the MHRA and is available on the NHS for adults with type 2 diabetes where blood glucose is not adequately controlled with other medications. It is prescribed under NHS guidance for T2D and can also provide meaningful weight loss as a secondary benefit. For weight loss as the primary goal, the NHS uses a different formulation: Wegovy (semaglutide 2.4 mg), approved under NICE Technology Appraisal TA964. Ozempic itself is not approved in the UK for obesity as a standalone indication, which leads to frequent confusion. However, private clinics and online prescribing services in the UK do offer Ozempic off-label for weight management. This guide explains the difference between Ozempic and Wegovy on the NHS, who qualifies for NHS prescriptions, what private Ozempic costs in the UK, and how to navigate the options available.

Ozempic vs Wegovy: Understanding the NHS Distinction

Ozempic and Wegovy are both semaglutide — the same active molecule — but they are licensed for different purposes at different doses. Ozempic (0.5 mg, 1 mg, 2 mg) is licensed for type 2 diabetes. Wegovy (2.4 mg) is licensed specifically for chronic weight management in adults with obesity or overweight plus comorbidities. On the NHS, this distinction matters enormously. GPs and diabetes teams can prescribe Ozempic for type 2 diabetes. But NHS weight loss prescriptions must go through the NICE-approved Wegovy pathway — not Ozempic. This means that if you have T2D, you may get semaglutide (as Ozempic) on the NHS as part of your diabetes care, with meaningful weight loss as a side benefit. If you want it purely for weight loss, the NHS pathway leads to Wegovy through a Tier 3 specialist service. Prescribing Ozempic off-label for weight loss on the NHS is generally not supported by commissioners.

• Ozempic (0.5–2 mg): NHS-prescribed for type 2 diabetes management
• Wegovy (2.4 mg): NHS-prescribed for obesity management via NICE TA964
• Both contain semaglutide — same molecule, different licensed doses
• Ozempic is NOT routinely prescribed on the NHS for weight loss without T2D
• Private clinics can prescribe Ozempic off-label for weight loss

Who Qualifies for Ozempic on the NHS?

Ozempic is available on the NHS for adults with type 2 diabetes when other treatments have not adequately controlled blood glucose. NICE guidance (TA572 and related guidance) covers when semaglutide should be offered as part of T2D management. Generally, it is considered when metformin and one or two other oral diabetes medications have not achieved adequate glycaemic control (HbA1c typically above 58 mmol/mol despite treatment), or when a GLP-1 receptor agonist is otherwise indicated due to cardiovascular risk. Patients with T2D who are prescribed Ozempic on the NHS will also experience weight loss — the average weight loss with Ozempic 1 mg in T2D trials is approximately 5–7%. This is a legitimate and intended benefit, though it is secondary to the primary T2D indication for NHS prescribing purposes. Weight loss alone is not sufficient to justify NHS Ozempic — a T2D diagnosis is required.

• Must have a type 2 diabetes diagnosis
• HbA1c not adequately controlled (typically >58 mmol/mol) on current medications
• Other medications (e.g., metformin, SGLT-2 inhibitors) tried first
• High cardiovascular risk may increase eligibility
• Weight loss without T2D: not a valid NHS Ozempic indication — Wegovy pathway applies instead

Wegovy on the NHS: The Weight Loss Route

For weight management without T2D, NICE TA964 (approved 2023) recommends Wegovy (semaglutide 2.4 mg) for adults with a BMI of 35 kg/m² or above (or 30+ for high-risk ethnic groups) and at least one weight-related comorbidity. Like Mounjaro, Wegovy must be prescribed through a specialist Tier 3 weight management service — GPs cannot prescribe it independently. NHS England has set out a phased rollout for Wegovy, with access expanded over time as Tier 3 services build capacity. In 2026, availability continues to grow but waiting times vary by ICB. Patients enrolled in eligible Tier 3 services who meet the criteria can access Wegovy at no cost (standard prescription charge applies or free if exempt). The treatment is limited to 2 years with mandatory milestone checks.

• NICE TA964 approved Wegovy (semaglutide 2.4 mg) for NHS weight management
• Eligibility: BMI ≥35 (or ≥30 for high-risk ethnic groups) + ≥1 comorbidity
• Prescribed only through Tier 3 specialist services — not by GPs
• NHS cost: standard prescription charge (~£9.90/item) or free if exempt
• Treatment limited to 2 years with milestone weight loss checks

Private Ozempic in the UK: Cost and Providers

If you want Ozempic for weight loss and do not have T2D — or you cannot access NHS Wegovy quickly — private prescriptions are available across the UK. Several online services and private clinics offer Ozempic prescriptions for weight management, typically at a cost of £150–220 per month depending on dose. The 0.5 mg starting dose is cheapest; the 2 mg maintenance dose is at the top of the range. Major UK providers offering private semaglutide include Boots (via its online doctor service), Superdrug Online Doctor, Juniper, Manual, and various private obesity clinics. Most require an online or in-person consultation with a prescribing clinician before issuing a prescription. Some services also offer compounded semaglutide at lower cost, though patients should be cautious about the regulatory status and quality assurance of compounded products.

• Private Ozempic cost: ~£150–220/month depending on dose
• 0.5 mg starting dose: ~£150–170/month
• 2 mg maintenance dose: ~£200–220/month
• Providers: Boots Online Doctor, Superdrug Online Doctor, Juniper, Manual, private clinics
• Consultation fee: typically £50–100 one-off or per review
• Compounded semaglutide: cheaper but regulatory caution advised

Ozempic Shortage in the UK: What You Should Know

Ozempic has faced supply shortages in the UK since 2022, driven by surging demand for off-label weight loss use. The MHRA and NHS England have periodically issued guidance asking prescribers to prioritise Ozempic for T2D patients and to refer weight loss patients to Wegovy instead. In 2026, supply has improved but remains subject to periodic constraints. Patients relying on Ozempic for T2D should not switch without consulting their prescriber. Private prescriptions may be subject to availability fluctuations. The British Medical Association (BMA) and NHS England have both issued guidance encouraging appropriate prescribing to protect supply for T2D patients who depend on the drug for glycaemic control.

Ozempic Side Effects: UK Patient Experience

The most commonly reported side effects of Ozempic in the UK (consistent with global trial data) are gastrointestinal: nausea, vomiting, diarrhoea, and constipation. These are most pronounced during dose escalation and typically improve after a few weeks at a stable dose. In UK NHS practice, Ozempic is started at 0.25 mg per week for 4 weeks before escalating to 0.5 mg, with further increases as tolerated. Rarer but more serious side effects include pancreatitis, gallbladder problems, and — in those with a personal or family history — a theoretical risk of thyroid C-cell tumours based on animal data. UK prescribers follow MHRA guidance on contraindications, which include a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2). Any new or worsening abdominal pain should be reported to a prescriber promptly.

• Common: nausea, vomiting, diarrhoea, constipation — usually peak at dose escalation
• Improved with slow titration: start at 0.25 mg/week for 4 weeks
• Rare but serious: pancreatitis, gallbladder disease
• Contraindicated in personal/family history of medullary thyroid carcinoma or MEN2
• Injection site reactions possible — rotate sites weekly

References

1. NICE Technology Appraisal TA964: Semaglutide for Managing Overweight and Obesity (2023)
2. NICE Technology Appraisal TA572: Semaglutide for Type 2 Diabetes (2019)
3. MHRA: Ozempic (Semaglutide) Product Information and UK Prescribing Guidance (2022)
4. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) (2021) — PubMed